MXPA05010575A - Peptacuerpo para el tratamiento del cancer. - Google Patents

Peptacuerpo para el tratamiento del cancer.

Info

Publication number
MXPA05010575A
MXPA05010575A MXPA05010575A MXPA05010575A MXPA05010575A MX PA05010575 A MXPA05010575 A MX PA05010575A MX PA05010575 A MXPA05010575 A MX PA05010575A MX PA05010575 A MXPA05010575 A MX PA05010575A MX PA05010575 A MXPA05010575 A MX PA05010575A
Authority
MX
Mexico
Prior art keywords
isolated
recombinant fusion
peptabody
fusion peptabody
cancer treatment
Prior art date
Application number
MXPA05010575A
Other languages
English (en)
Inventor
Omar Fattah
Original Assignee
Univ Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Lausanne filed Critical Univ Lausanne
Publication of MXPA05010575A publication Critical patent/MXPA05010575A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invencion se refiere a un peptacuerpo de fusion aislado y recombinante, que se enlaza a un miembro de la familia de receptores del factor de crecimiento epidermico, util en la inhibicion del crecimiento de ciertas celulas tumorales. Se describen tambien los acidos nucleicos que codifican para el peptacuerpo de fusion aislado y recombinante, los equipos y las composiciones farmaceuticas que comprenden el peptacuerpo de fusion aislado y recombinante, como una sustancia activa. Finalmente, se proporciona un metodo para la fabricacion del peptacuerpo de fusion aislado y recombinante, y su uso para la preparacion de un medicamento para el tratamiento o prevencion del cancer.
MXPA05010575A 2003-04-04 2004-04-05 Peptacuerpo para el tratamiento del cancer. MXPA05010575A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46049003P 2003-04-04 2003-04-04
PCT/IB2004/001049 WO2004087766A2 (en) 2003-04-04 2004-04-05 Peptabody for cancer treatment

Publications (1)

Publication Number Publication Date
MXPA05010575A true MXPA05010575A (es) 2006-03-09

Family

ID=33131924

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010575A MXPA05010575A (es) 2003-04-04 2004-04-05 Peptacuerpo para el tratamiento del cancer.

Country Status (12)

Country Link
US (1) US20060233808A1 (es)
EP (1) EP1613661B1 (es)
JP (1) JP2007527206A (es)
KR (1) KR20060017585A (es)
CN (1) CN1798770B (es)
AT (1) ATE514718T1 (es)
AU (1) AU2004226162A1 (es)
BR (1) BRPI0409554A (es)
CA (1) CA2521393A1 (es)
MX (1) MXPA05010575A (es)
NO (1) NO20055209L (es)
WO (1) WO2004087766A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2643478C (en) * 2006-02-23 2019-06-18 Novocell, Inc. Compositions and methods useful for culturing differentiable cells
WO2009103072A2 (en) * 2008-02-14 2009-08-20 The Trustees Of The University Of Pennsylvania Erbb4 inhibitors and uses thereof in treatment of neuropsychiatric disorders
WO2010033249A2 (en) * 2008-09-22 2010-03-25 Massachusetts Institute Of Technology Compositions of and methods using ligand dimers
AU2009314534B2 (en) 2008-11-12 2014-06-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ERBB4 as a prognostic and therapeutic marker for melanoma
CA2753282C (en) 2009-03-10 2017-11-28 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
US9168297B2 (en) 2010-06-23 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (NRG-1)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP2013540125A (ja) * 2010-09-30 2013-10-31 ゴラブ，エミール 水中細菌抽出物−濃縮物からの乾燥粉末の調製方法
KR101633159B1 (ko) * 2013-11-28 2016-06-23 부경대학교 산학협력단 클라미도모나스 유래 활성 펩타이드를 유효성분으로 포함하는 위장 질환 치료 및 예방용 조성물
KR101587622B1 (ko) 2014-05-23 2016-01-22 한국과학기술원 상피세포 성장인자 수용체의 세포외 도메인과 결합하는 신규 폴리펩타이드
WO2019086394A1 (en) * 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
CA3091423A1 (en) * 2018-02-15 2019-08-22 Children's National Medical Center Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
CN116370335A (zh) * 2021-12-31 2023-07-04 康码（上海）生物科技有限公司 用于擦拭的病毒防护溶液以及病毒防护擦拭产品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571507A (en) * 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
WO1994018345A1 (en) * 1993-02-05 1994-08-18 Affymax Technologies N.V. Receptor-binding antiproliferative peptides
WO1998018943A1 (en) * 1996-10-28 1998-05-07 Novartis Ag Method for the oligomerisation of peptides
CA2297692A1 (en) * 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
WO2001005433A2 (en) * 1999-07-14 2001-01-25 Board Of Regents, The University Of Texas System Delivery and retention of activity agents to lymph nodes
EP2267026A1 (en) * 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
EP1301612A2 (en) * 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
AU2001273559A1 (en) * 2000-07-18 2002-01-30 Enchira Biotechnology Corporation Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
DE10108100A1 (de) * 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
PL363322A1 (en) * 2001-05-08 2004-11-15 Merck Patent Gmbh Combination therapy using anti-egfr antibodies and anti-hormonal agents
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule

Also Published As

Publication number Publication date
WO2004087766A2 (en) 2004-10-14
EP1613661B1 (en) 2011-06-29
CN1798770B (zh) 2010-06-09
KR20060017585A (ko) 2006-02-24
ATE514718T1 (de) 2011-07-15
BRPI0409554A (pt) 2006-04-25
WO2004087766A3 (en) 2004-12-16
AU2004226162A1 (en) 2004-10-14
NO20055209D0 (no) 2005-11-04
NO20055209L (no) 2006-01-02
CN1798770A (zh) 2006-07-05
JP2007527206A (ja) 2007-09-27
EP1613661A2 (en) 2006-01-11
US20060233808A1 (en) 2006-10-19
CA2521393A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
NO20055209D0 (no) Peptabody for cancerbehandling
DE60028970D1 (de) An her2 bindende peptidverbindungen
MX2009003729A (es) Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a.
YU44404A (sh) Postupak za identifikovanje ciljnih enzima tumora
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
AU2002305450A1 (en) Proteomimetic compounds and methods
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
RS20100555A (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
MX2010006211A (es) Proteínas elastasa recombinantes y métodos de fabricación y uso de las mismas.
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2006047728A3 (en) Bmp gene and fusion protein
HK1078593A1 (en) Antibody against a tumor-specific antigen as target
WO2007109648A3 (en) Compositions and methods for modulating store-operated calcium entry
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
WO2001057069A3 (en) Targeting peptides
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
WO2006029406A3 (en) Methods for treating bone tumors using bone morphogenic proteins
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
JO3046B1 (ar) اشكال متعددة من 7- )] 3-كلورو-6و11-ثنائي هيدرو -6-ميثيل ثنائي بنزو [1, 2][f,c] ثيازبين-11-يل)امينو[ حمض هباتونك S,S- ثنائي أوكسيد وطرق لتصنيعها و استخدامها.